List of Excipients in Branded Drug BREO ELLIPTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	BREO ELLIPTA	fluticasone furoate and vilanterol trifenatate	0173-0859	LACTOSE MONOHYDRATE	2026-05-13
GlaxoSmithKline LLC	BREO ELLIPTA	fluticasone furoate and vilanterol trifenatate	0173-0859	MAGNESIUM STEARATE	2026-05-13
GlaxoSmithKline LLC	BREO ELLIPTA	fluticasone furoate and vilanterol trifenatate	0173-0916	LACTOSE MONOHYDRATE	2026-05-13
GlaxoSmithKline LLC	BREO ELLIPTA	fluticasone furoate and vilanterol trifenatate	0173-0916	MAGNESIUM STEARATE	2026-05-13
REMEDYREPACK INC	BREO ELLIPTA	fluticasone furoate and vilanterol trifenatate	70518-2028	LACTOSE MONOHYDRATE	2026-05-13
REMEDYREPACK INC	BREO ELLIPTA	fluticasone furoate and vilanterol trifenatate	70518-2028	MAGNESIUM STEARATE	2026-05-13

Breo Ellipta Excipient Strategy and Commercial Opportunities

Last updated: September 17, 2026

Breo Ellipta is a once-daily dry-powder inhaler containing fluticasone furoate and vilanterol trifenatate. Its commercial value comes from the combined drug substance, low-dose carrier-based powder, proprietary Ellipta inhaler, and manufacturing controls needed to deliver a consistent emitted dose. The principal excipient opportunity is lactose-based inhalation-grade carrier technology, with smaller opportunities in magnesium stearate lubrication, engineered particle blends, device components, and generic-device development.

What is Breo Ellipta and how does its formulation work?

Breo Ellipta is GSK’s inhaled corticosteroid and long-acting beta2-adrenergic agonist combination. In the United States, it is marketed as Breo Ellipta 100/25 and 200/25 micrograms, containing fluticasone furoate and vilanterol delivered once daily through the Ellipta dry-powder inhaler.[1]

Product attribute	Breo Ellipta
Active ingredients	Fluticasone furoate and vilanterol
Drug classes	Inhaled corticosteroid and long-acting beta2 agonist
Dosage form	Inhalation powder
Delivery system	Ellipta multi-dose dry-powder inhaler
U.S. strengths	100/25 mcg and 200/25 mcg
Main indications	COPD maintenance treatment; asthma maintenance treatment
Route	Oral inhalation
Primary commercial owner	GSK
Core excipient platform	Lactose monohydrate carrier with magnesium stearate
Administration	Once daily

The powder is held in foil blister strips inside the inhaler. Opening the cover exposes a dose, and the patient’s inhalation disperses the powder into an aerosol. The formulation must balance powder flow, deagglomeration, dose uniformity, aerodynamic performance, moisture resistance, and chemical stability.

What excipients are used in Breo Ellipta?

The principal excipients identified in the U.S. prescribing information are lactose monohydrate and magnesium stearate.[1]

Lactose monohydrate

Lactose monohydrate is the bulk carrier in the formulation. The active ingredients are present at microgram-scale doses, while the carrier improves powder handling and metering. Lactose also supports the formation of drug-carrier agglomerates that separate during inhalation.

The commercial requirements for lactose are more demanding than for ordinary oral solid-dose lactose. Relevant attributes include:

• Particle-size distribution
• Fine-particle fraction
• Morphology and surface roughness
• Moisture content
• Crystallinity and polymorphic profile
• Flowability
• Electrostatic behavior
• Microbial quality
• Lot-to-lot consistency

An excipient supplier that can offer tightly controlled inhalation-grade lactose, supported by aerodynamic performance data, has a commercially relevant position in this market.

Magnesium stearate

Magnesium stearate is used at a low concentration to modify surface properties and improve powder processing. In inhalation powders, it can reduce cohesion, improve flow, limit moisture interaction, and alter drug detachment from the carrier.

The formulation impact depends on:

• Grade and fatty-acid composition
• Particle-size distribution
• Mixing intensity
• Coating distribution
• Powder residence time
• Relative humidity
• Interaction with lactose and active pharmaceutical ingredients

Magnesium stearate is therefore not a simple commodity input in this application. A supplier with inhalation-specific grades and validated blending performance can compete on formulation performance rather than price alone.

How does the Breo Ellipta powder formulation create commercial barriers?

The principal barrier is the interaction between formulation and device. A substitute formulation must reproduce the delivered dose and aerodynamic particle-size distribution through the intended inhaler or an equivalent device.

Critical quality attributes include:

Attribute	Commercial significance
Delivered dose uniformity	Determines whether the patient receives the labeled dose
Fine-particle mass	Influences lung deposition
Mass median aerodynamic diameter	Affects regional airway delivery
Moisture uptake	Can cause agglomeration and dose variability
Powder flow	Affects metering and emptying of the blister
Blend uniformity	Important because active doses are low
Chemical stability	Protects fluticasone furoate and vilanterol during shelf life
Device resistance	Affects performance across patient inhalation profiles
Dose counter accuracy	Affects patient use and adherence
Blister seal integrity	Controls moisture ingress

A generic company cannot rely solely on chemical equivalence. It must establish pharmaceutical equivalence, device performance, aerodynamic equivalence, and clinical or comparative evidence required by the applicable regulatory pathway.

What formulation patents protect Breo Ellipta?

Breo Ellipta protection is distributed across several potential patent categories:

1. Fluticasone furoate composition and crystalline-form patents.
2. Vilanterol and vilanterol trifenatate composition patents.
3. Combination-product patents.
4. Dry-powder formulation patents.
5. Blister-strip and moisture-protection patents.
6. Ellipta inhaler and dose-dispensing patents.
7. Manufacturing and powder-processing patents.
8. Method-of-use patents covering COPD or asthma treatment.

The strongest commercial protection is usually the combination of formulation and device rights. A competitor may avoid a single formulation claim but still face infringement exposure through the inhaler, blister configuration, powder-processing method, or method-of-treatment claims.

Patent scope must be distinguished from FDA Orange Book listing. The Orange Book identifies patents submitted to FDA for approved products, but it does not provide a complete record of every potentially relevant patent or determine infringement.[2]

What is the Orange Book and exclusivity status of Breo Ellipta?

Breo Ellipta was approved in the United States in 2013 for COPD maintenance treatment under NDA 204275. FDA later approved the product for asthma maintenance treatment.[1,3]

Regulatory event	Date or status
U.S. COPD approval	2013
U.S. asthma approval	2015
New chemical entity exclusivity	Five-year period beginning with the initial approval
Pediatric exclusivity	Applies only if separately granted and reflected in FDA records
Current regulatory category	Approved inhaled combination product
Generic substitution	Not established through a conventional tablet-style substitution model
Biosimilar pathway	Not applicable

The original five-year new chemical entity exclusivity period has expired. That does not mean generic entry is unrestricted. Patent rights, device complexity, formulation equivalence, manufacturing capability, and regulatory requirements remain relevant.

For Breo Ellipta, an ANDA applicant would typically evaluate whether it can use an appropriate suitability or equivalence pathway for a combination inhalation product. FDA may require comparative in vitro performance, pharmacokinetic evidence, pharmacodynamic evidence, or other studies depending on the proposed product and regulatory route.[4]

When does Breo Ellipta lose exclusivity?

Breo Ellipta lost its initial statutory new chemical entity exclusivity years after its 2013 approval. Commercial exclusivity now depends primarily on patent expiration, litigation outcomes, regulatory approval of competing inhalers, and the ability of a challenger to establish substitutable performance.

A single “loss of exclusivity” date is not sufficient for Breo Ellipta because:

• Different patents may expire in different years.
• Device patents may have terms distinct from drug-substance patents.
• Pediatric exclusivity can extend certain listed patent or exclusivity periods.
• A patent settlement may establish an agreed launch date before the latest patent expiration.
• A competitor may enter with a non-infringing device or formulation rather than challenge every claim.

The commercially relevant assessment should therefore use a patent-family and claim-by-claim timeline rather than a single headline expiration date.

What are the Paragraph IV risks for Breo Ellipta?

A generic applicant that files an ANDA with a Paragraph IV certification may allege that a listed patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation if the patent owner brings suit within the statutory period.

Potential Paragraph IV targets include:

• Combination-product claims covering fluticasone furoate and vilanterol.
• Powder composition claims involving lactose and magnesium stearate.
• Blister or foil-strip claims.
• Inhaler architecture and dose-delivery claims.
• Use claims for COPD or asthma.
• Manufacturing claims involving powder blending or filling.

Paragraph IV risk is higher where the product depends on a proprietary inhaler and where the reference listed drug has several overlapping patent families. The challenger must also manage the possibility that it obtains approval but cannot commercially launch because the proposed device or formulation remains exposed to a separate patent family.

What generic entry scenarios exist for Breo Ellipta?

Scenario 1: Device-specific generic entry

A challenger develops an inhaler that is sufficiently equivalent for FDA purposes but does not copy the Ellipta device. This approach may reduce device-patent risk but increases development and human-factors costs.

Scenario 2: Formulation challenge with a similar device

The applicant uses a comparable blister-based inhaler and challenges formulation or combination patents. This can reduce development risk but may increase litigation exposure.

Scenario 3: Authorized generic or license arrangement

GSK could commercialize or license a competing product under negotiated terms. This would protect part of the franchise while allowing controlled price competition.

Scenario 4: Non-substitutable therapeutic competition

A competitor may target the same COPD or asthma population with another inhaled corticosteroid/long-acting beta agonist combination. Such products compete commercially without being therapeutically or pharmaceutically substitutable.

Which companies compete with Breo Ellipta?

The principal competitive set includes other inhaled corticosteroid and long-acting beta agonist products:

Product	Active ingredients	Company or major commercial sponsor
Breo Ellipta	Fluticasone furoate/vilanterol	GSK
Advair Diskus and authorized or generic equivalents	Fluticasone propionate/salmeterol	GSK and generic manufacturers
Dulera	Mometasone/formoterol	Organon and partners
Symbicort	Budesonide/formoterol	AstraZeneca and generic manufacturers
AirDuo and related products	Fluticasone propionate/salmeterol	Teva and partners

Breo Ellipta differentiates itself through once-daily dosing and the Ellipta inhaler. Its commercial vulnerability is greater where payers favor lower-cost alternatives, where patients can use twice-daily products successfully, or where generic versions of competing inhalers are available.

What excipient opportunities exist for suppliers?

Inhalation-grade lactose

This is the clearest opportunity. Suppliers can differentiate through:

• Controlled fine-particle content
• Low-moisture grades
• Defined surface morphology
• Consistent carrier performance
• Reduced electrostatic variability
• Regulatory support for inhalation use
• Compatibility with high-shear and low-shear blending

Engineered carrier particles

Co-processed lactose or engineered carrier systems could improve active detachment, reduce dose variability, or enable lower carrier loads. Such materials may support differentiated products if they produce a measurable performance advantage and can be manufactured at scale.

Magnesium stearate systems

Suppliers can offer inhalation-specific magnesium stearate grades or pre-engineered carrier systems. The opportunity is strongest where the material improves powder flow and emitted-dose consistency without impairing active-particle detachment.

Moisture-control materials

The blister and package system is critical because moisture can alter powder cohesion and aerosolization. Commercial opportunities include improved foil laminates, desiccant systems, moisture-barrier coatings, and packaging designs that preserve performance across temperature and humidity conditions.

Device-compatible formulation platforms

Companies can develop powder platforms optimized for multi-dose blister inhalers, capsule-based inhalers, or reservoir devices. The commercial value increases when the platform supports several corticosteroid, bronchodilator, or combination products.

How strong is the Breo Ellipta patent estate?

The estate is commercially meaningful because it can combine active-ingredient, formulation, device, and manufacturing claims. Its strength depends on the surviving claims, prosecution history, terminal disclaimers, continuation practice, and the jurisdiction.

Patent layer	Likely commercial role
Active ingredient	Protects chemical entities and salt forms
Combination	Protects use of both actives in one product
Formulation	Protects carrier, lubricant, ratios, and powder properties
Device	Protects inhaler mechanics and dose dispensing
Packaging	Protects moisture-controlled blister systems
Manufacturing	Protects blending, filling, and powder-processing steps
Method of use	Protects treatment of COPD or asthma

The estate is stronger when these layers overlap and weaker when a challenger can use a different inhaler, formulation, and manufacturing process without practicing asserted claims.

What litigation and settlement issues affect generic entry?

Relevant disputes may involve:

• Whether a proposed inhaler is within the scope of device claims.
• Whether the generic has the same active ingredients and dosage form.
• Whether formulation differences affect pharmaceutical equivalence.
• Whether method-of-use claims are properly carved out.
• Whether a listed patent is valid after obviousness review.
• Whether a patent settlement delays launch or permits an earlier entry date.

A settlement can be more commercially important than a final judgment because it may establish a binding launch date, royalty structure, authorized-generic terms, or restrictions on product configurations. Deal terms are not always public, and a public litigation dismissal does not necessarily disclose the complete commercial arrangement.

What manufacturing and intellectual-property barriers exist?

Breo Ellipta manufacturing requires:

• Micronized active pharmaceutical ingredients
• Controlled carrier blending
• Low-dose content uniformity
• Specialized blister filling
• High-integrity foil sealing
• Device assembly
• Automated dose-counting and actuation controls
• Stability testing under humidity stress
• Aerodynamic performance testing

The manufacturing barrier is highest for companies attempting to reproduce both the powder and the device. A formulation-only supplier may have a lower-risk commercial opportunity by selling excipients, engineered carriers, or contract development services rather than launching a competing finished product.

How does Breo Ellipta compare with Advair and Symbicort?

Attribute	Breo Ellipta	Advair	Symbicort
Corticosteroid	Fluticasone furoate	Fluticasone propionate	Budesonide
Long-acting bronchodilator	Vilanterol	Salmeterol	Formoterol
Common device	Ellipta	Diskus or HFA inhaler, depending on product	Turbuhaler or HFA inhaler, depending on market
Dosing frequency	Once daily	Commonly twice daily	Commonly twice daily
Generic competition	More complex inhaled-product pathway	Established generic competition in some presentations	Generic competition in some markets
Excipient opportunity	Carrier and device compatibility	Carrier, suspension, and device-specific systems	Carrier, suspension, and device-specific systems

Breo Ellipta’s once-daily schedule is its principal product advantage. Advair has a larger historical installed base, while Symbicort benefits from broad market familiarity and established generic competition in certain jurisdictions.

Key Takeaways

• Breo Ellipta uses lactose monohydrate and magnesium stearate in a carrier-based dry-powder formulation.
• The strongest excipient opportunity is inhalation-grade lactose with tightly controlled particle size, morphology, moisture, and flow properties.
• Magnesium stearate can create value through powder-flow and surface-engineering performance, but it is unlikely to be commercially differentiated as an undifferentiated commodity.
• Generic entry is constrained by the combined formulation, device, blister, manufacturing, and regulatory requirements.
• The initial five-year new chemical entity exclusivity period has expired; remaining commercial protection depends on patents, device rights, litigation, and market competition.
• Breo Ellipta’s main commercial differentiation is once-daily administration through the Ellipta inhaler.
• Engineered carrier particles, moisture-control packaging, and device-compatible powder platforms offer the most credible adjacent commercial opportunities.
• Patent analysis should separate active-ingredient, formulation, device, manufacturing, and method-of-use claims rather than rely on a single expiry date.

FAQs

What is the main excipient in Breo Ellipta?

Lactose monohydrate is the principal carrier excipient. Magnesium stearate is used as a low-level powder-processing and surface-modifying excipient.

Can a generic company use a different excipient from Breo Ellipta?

Yes, if the proposed product meets FDA requirements for pharmaceutical equivalence, performance, safety, and therapeutic equivalence. A different carrier may create additional development and regulatory obligations.

Is Breo Ellipta a biologic eligible for biosimilar competition?

No. Breo Ellipta is a small-molecule inhaled combination product. Biosimilar rules do not apply.

What is the most attractive licensing opportunity around Breo Ellipta?

The strongest opportunities are inhalation-grade lactose, engineered carrier systems, magnesium-stearate surface treatment, moisture-barrier packaging, and contract development of dry-powder inhaler formulations.

Does expiry of a Breo Ellipta patent guarantee immediate generic substitution?

No. Generic substitution depends on FDA approval, applicable patent rights, device and formulation equivalence, state substitution rules, and the commercial launch terms agreed in any patent settlement.

References

1. U.S. Food and Drug Administration. (2024). Breo Ellipta prescribing information. GlaxoSmithKline LLC.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2015). FDA approves Breo Ellipta for asthma.
4. U.S. Food and Drug Administration. (2023). Draft guidance on fluticasone furoate; vilanterol trifenatate inhalation powder.
5. GlaxoSmithKline plc. (2024). Annual report 2023.